Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The sartans are coming!

D Jack1

  • 1MWEC, Glasgow, Scotland. 100344.1432@compuserve.com

Drug News & Perspectives
|August 26, 2003
PubMed
Summary
This summary is machine-generated.

New angiotensin II receptor antagonists, or "sartans," offer improved side effect profiles for hypertension management. Research is ongoing to explore their broader therapeutic roles beyond blood pressure control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.

Journal of neurology·2023
Same author

Using longitudinal survey and sensor data to understand the social and ecological determinants of clean fuels use and discontinuance in rural Ghana.

Environmental research communications·2021
Same author

Deliberating performance targets workshop: Potential paths for emerging PM<sub>2.5</sub> and O<sub>3</sub> air sensor progress.

Atmospheric Environment: X·2021
Same author

High sensitivity troponin T provides useful prognostic information in non-acute chest pain.

QJM : monthly journal of the Association of Physicians·2011
Same author

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.

Respiratory medicine·2010
Same author

TDM: the key to more effective HIV treatment?

Drug news & perspectives·2003
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The 3rd International Symposium on Angiotensin II Antagonism convened in London, March 2000.
  • Company-sponsored symposia focused on "sartan" drugs, a class of angiotensin II receptor antagonists.
  • Sartans emerged in the 1990s, valued for fewer side effects compared to other antihypertensives.

Purpose of the Study:

  • To review advancements and ongoing research in angiotensin II antagonism.
  • To highlight new sartan combinations and clinical trial data presented at the symposium.
  • To address the evolving role of sartans in cardiovascular medicine.

Main Methods:

  • Symposium presentations and discussions.
  • Review of company-sponsored symposia on sartan drugs.
  • Presentation of new clinical trial data for candesartan cilexetil + hydrochlorothiazide.

Related Experiment Videos

Main Results:

  • Losartan and valsartan have established successful combinations with hydrochlorothiazide.
  • A new combination, candesartan cilexetil + hydrochlorothiazide, was announced.
  • New clinical trial data for this combination were presented at the meeting.

Conclusions:

  • Sartans represent a significant advancement in antihypertensive therapy due to their favorable side effect profiles.
  • Ongoing megastudies are expected to clarify the role of sartans in conditions beyond hypertension.
  • Further research is crucial to fully elucidate the therapeutic potential of angiotensin II receptor antagonists.